About: COMPLEMENT ACTIVATION IN PATIENTS WITH COVID-19: A NOVEL THERAPEUTIC TARGET

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COMPLEMENT ACTIVATION IN PATIENTS WITH COVID-19: A NOVEL THERAPEUTIC TARGET Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COMPLEMENT ACTIVATION IN PATIENTS WITH COVID-19: A NOVEL THERAPEUTIC TARGET
Creator	Blasi, Francesco Aliberti, Stefano Tedesco, Francesco Gualtierotti, Roberta Meroni, Pier Panigada, Mauro Peyvandi, Flora Cugno, Massimo Griffini, Samantha Grovetti, Elena Pl, Meroni Torri, Adriana
Source	Elsevier; Medline; PMC
abstract	The pathophysiology of the severe complications of COVID-19 is still unclear. We report preliminary data providing evidence of complement activation in patients with COVID-19 with different degrees of respiratory failure.
has issue date	2020-05-14(xsd:dateTime)
bibo:doi	10.1016/j.jaci.2020.05.006
bibo:pmid	32417135
has license	els-covid
sha1sum (hex)	898e756b8c2b08a3f01f3fed8f9a941fa7b12e3b
schema:url	https://doi.org/10.1016/j.jaci.2020.05.006
resource representing a document's title	COMPLEMENT ACTIVATION IN PATIENTS WITH COVID-19: A NOVEL THERAPEUTIC TARGET
has PubMed Central identifier	PMC7224678
has PubMed identifier	32417135
schema:publication	J Allergy Clin Immunol
resource representing a document's body	covid:898e756b8c2b08a3f01f3fed8f9a941fa7b12e3b#body_text
is schema:about of	named entity 'COVID-19' named entity 'COVID-19' named entity 'THERAPEUTIC TARGET' named entity 'COVID-19' named entity 'complement' named entity 'plasma' named entity 'continuous positive airway pressure' named entity 'C5a' named entity 'COVID-19' named entity 'COVID' named entity 'disease outcome' named entity 'solid organ' named entity 'lung' named entity 'tissue injury' named entity 'COVID' named entity 'prothrombotic' named entity 'COVID' named entity 'fibrinogen' named entity 'assay' named entity 'SARS-CoV-2' named entity 'endothelial cells' named entity 'neutrophils' named entity 'CRP' named entity 'Quidel Corporation' named entity 'C5a' named entity 'COVID' named entity 'eculizumab' named entity 'inflammatory response' named entity 'ng/mL' named entity 'bone marrow' named entity 'serine protease' named entity 'viral infection' named entity 'endothelial' named entity 'fibrin' named entity 'lung' named entity 'complement activation' named entity 'aPTT' named entity 'ng/mL' named entity 'San Diego' named entity 'dyspnea' named entity 'CRP' named entity 'infectious agents' named entity 'independent variables' named entity 'COVID' named entity 'C5b' named entity 'correlation' named entity 'activated partial thromboplastin time' named entity 'COVID-19.' named entity 'plasma levels' named entity 'cough' named entity 'white blood cells' named entity 'inflammation' named entity 'complete remission' named entity 'complement activation' named entity 'viruses' named entity 'complement activation' named entity 'severe pneumonia' named entity 'life-threatening' named entity 'C-reactive protein' named entity 'endothelial cells' named entity 'statistically significant' named entity 'interleukin-6' named entity 'EDTA' named entity 'complement' named entity 'lymphocytes' named entity 'signs and symptoms' named entity 'coagulation' named entity 'respiratory failure' named entity 'complement activation' named entity 'minimum-maximum'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software